ISU Abxis Co., Ltd. (KOSDAQ:086890)
3,260.00
-5.00 (-0.15%)
At close: Jun 5, 2026
Dialog Axiata Revenue
ISU Abxis had revenue of 9.45B KRW in the quarter ending March 31, 2026, with 31.59% growth. This brings the company's revenue in the last twelve months to 58.94B, up 15.73% year-over-year. In the year 2025, ISU Abxis had annual revenue of 56.67B, down -5.95%.
Revenue (ttm)
58.94B
Revenue Growth
+15.73%
P/S Ratio
2.26
Revenue / Employee
331.13M
Employees
178
Market Cap
132.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.67B | -3.59B | -5.95% |
| Dec 31, 2024 | 60.26B | 5.95B | 10.96% |
| Dec 31, 2023 | 54.31B | 13.14B | 31.91% |
| Dec 31, 2022 | 41.17B | 13.15B | 46.94% |
| Dec 31, 2021 | 28.02B | 2.41B | 9.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cell Biotech | 56.49B |
| Genome & Company | 24.02B |
| CORESTEMCHEMON | 18.39B |
| Prestige Biologics | 18.03B |
| Bio Solution | 15.82B |
| TiumBio | 13.13B |
| QuadMedicine | 9.78B |
| NovMetaPharma | 1.30B |